Anemia in myelofibrosis: Current and emerging treatment options
Myelofibrosis (MF) is really a clonal hematologic malignancy with progressive bone marrow fibrosis. Clinical manifestations of MF include splenomegaly, constitutional signs and symptoms, and anemia, whose pathogenesis is multifactorial and largely because of ineffective erythropoiesis and it is clinically connected with low quality of existence and reduced overall survival. The only real curative strategy to MF is allogenic stem cell transplantation however, couple of people are qualified. Disease management techniques for MF-related anemia have limited effectiveness, and Janus kinase (JAK) inhibitors may induce or worsen related anemia. Thus, there’s a substantial unmet need to treat patients with MF-related anemia. This review CPI-0610 summarizes current and emerging treating anemia in MF, including luspatercept and KER-050 (transforming growth factor-ß ligand traps), momelotinib and pacritinib (JAK inhibitors), pelabresib (a bromodomain extra-terminal domain inhibitor), PRM-151 (an antifibrotic agent), imetelstat (a telomerase inhibitor), and navitoclax (a BCL-2/BCL-xL inhibitor). Therapeutic combinations with ruxolitinib offer another treatment approach.